Lung Cancer | Specialty

The OncLive Lung Cancer condition center page is a comprehensive resource for clinical news and expert insights on non–small cell lung cancer, small cell lung cancer, mesothelioma, and more. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in lung cancer.

Improved Understanding of Biomarkers in Tumor Microenvironment Key for Treatment Decisions in NSCLC

March 23rd 2023

Brian S. Henick, MD, discusses the importance of expanding on the current knowledge of biomarkers and the tumor microenvironment to enhance treatment approaches for patients with non–small cell lung cancer.

Dr Henick on Biomarker Detection in Lung Cancer

March 22nd 2023

Brian Henick, MD, discusses the different ways to identify biomarkers of immunotherapy response in patients with lung cancer and how refining these approaches may improve individualized treatment approaches in the future.

Dr Cummings on the Investigation of Osimertinib in EGFR-Mutant NSCLC

March 22nd 2023

Amy L. Cummings, MD, discusses the significance of the phase 3 FLAURA trial evaluating osimertinib in locally advanced or metastatic non–small cell lung cancer (NSCLC).

Adjuvant Pembrolizumab Expands Options for Patients with Resected Stage IB-IIIA NSCLC

March 21st 2023

Luis Paz-Ares, MD, PhD, highlight adverse events to monitor with pembrolizumab in this setting as well as its role in the treatment landscape.

Dr. Burns on the Evolving Use of ADCs in HER2-mutant NSCLC

March 21st 2023

Timothy Burns, MD, PhD, discusses the evolving use of antibody-drug conjugates in HER2-mutant non–small cell lung cancer.

Dr. Henick on Further Exploring the Immune Microenvironment in Lung Cancer

March 20th 2023

Brian Henick, MD, discusses the importance of further exploring biomarkers in the immune microenvironment for immunotherapy in patients with lung cancer.

Dr. Garon on the Current Landscape of PD-L1 and CTLA-4 Inhibitor Regimens in NSCLC

March 20th 2023

Edward B. Garon, MD, MS, discusses the use of PD-L1 inhibitor and CTLA-4 inhibitor combinations in non–small cell lung cancer.

Patritumab Deruxtecan Continues to Generate Responses in Previously Treated EGFR-Mutated NSCLC and HER3-Expressing Breast Cancer

March 20th 2023

Patritumab deruxtecan elicited responses in previously treated patients with EGFR-mutated metastatic or unresectable non–small cell lung cancer and patients with HER3-expressing metastatic breast cancer.

Immunotherapy and Targeted Therapies Continue to Improve Patient Outcomes in Lung Cancer

March 20th 2023

Updated data from key trials in non–small cell lung cancer continue to demonstrate the superiority of immunotherapy and targeted therapy regimens for non–small cell lung cancer treatment, but the optimal use of these agents in the adjuvant vs neoadjuvant settings is still contested.

Dr. Mitzman on Neoadjuvant Nivolumab Plus Chemotherapy in NSCLC

March 17th 2023

Brian Mitzman, MD, FACS, FCCP, discusses findings from the phase 3 CheckMate 816 trial in patients with resectable non–small cell lung cancer.

PARP7 Inhibitor RBN-2397 Has Tolerable Safety Profile in Solid Tumors

March 17th 2023

RBN-2397, a PARP7 inhibitor, was found to be well tolerated and have preliminary antitumor activity as monotherapy in patients with advanced solid tumors, including head and neck squamous cell carcinoma, breast cancer, and squamous cell carcinoma of the lung.

Vibostolimab/Pembrolizumab Coformulation Fails to Reach PFS End Point in Pretreated Metastatic NSCLC

March 17th 2023

A coformulation of pembrolizumab and vibostolimab did not elicit a statistically significant improvement in progression-free survival vs docetaxel in pretreated patients with metastatic non–small cell lung cancer.

Raez Reports Benefits of Liquid Biopsy in Newly Diagnosed NSCLC

March 16th 2023

Dr Raez discusses findings from a study of patients with newly diagnosed non–small cell lung cancer who received both liquid and tissue biopsy, the benefits of liquid biopsy’s relatively short turnaround time, and financial barriers to conducting multiple next-generation sequencing tests per patient.

Traveling Through the Lung Cancer Treatment Paradigm: Taking TKI-Related AEs Into Consideration for NSCLC

March 15th 2023

In this sixth episode of OncChats: Traveling Through the Lung Cancer Treatment Paradigm, Aaron Franke, MD, discusses the consideration of adverse effects related to treatment with TKIs patients in non–small cell lung cancer.

Adjuvant Targeted Therapies Could Continue to Shift the Treatment Paradigm in NSCLC

March 14th 2023

Adjuvant osimertinib and other targeted therapies, such as KRAS G12C inhibitors, could continue to change the perioperative treatment landscape in non–small cell lung cancer.

Pembrolizumab Plus Chemotherapy Meets OS End Point in Advanced Malignant Pleural Mesothelioma

March 10th 2023

First-line treatment with the combination of pembrolizumab and chemotherapy generated a statistically significant and clinically meaningful improvement in overall survival compared with chemotherapy alone in patients with unresectable advanced or metastatic malignant pleural mesothelioma.

FDA Approval Insights: Adjuvant Pembrolizumab in Stage IB, II, or IIIA NSCLC

March 9th 2023

Dr Herbst discusses the FDA approval of adjuvant pembrolizumab in non–small cell lung cancer, key efficacy and safety data from the KEYNOTE-091 trial, and future research efforts that may further improve outcomes in this population.

Adjuvant Osimertinib Elicits OS Improvement in Early-Stage EGFR-Mutated NSCLC

March 9th 2023

Osimertinib produced a statistically significant and clinically meaningful improvement in overall survival compared with placebo as adjuvant treatment for patients with stage IB, II, or IIIA, EGFR-mutated non–small cell lung cancer after complete tumor resection with curative intent.

Traveling Through the Lung Cancer Treatment Paradigm: Oral Etoposide

March 8th 2023

In this fifth episode of OncChats: Traveling Through the Lung Cancer Treatment Paradigm, Aaron Franke, MD, discusses instances where oral etoposide could be utilized for patients with small cell lung cancer.

FDA Expands Approval for Companion Diagnostic for Cemiplimab in NSCLC

March 7th 2023

The FDA has approved the VENTANA PD-L1 assay for expanded use in patients with advanced non–small cell lung cancer to help identify patients who may be candidates for treatment with cemiplimab.